

ZUBSOLV (buprenorphine/naloxone) sublingual tablet

Diagnosis Considered for Coverage:

- Maintenance treatment of opioid dependence as part of a complete treatment plan to include counseling and psychosocial support

Coverage Criteria:

For request up to 17.1 mg buprenorphine per day

- Not being used in combination with an opiate, **and**
- Medical rationale why patient is unable to use the buprenorphine/naloxone sublingual (Suboxone) tablet.

For request exceeding FDA label maximum up to 34.4 mg buprenorphine per day

- Provider attests patient is experiencing withdrawal or increased cravings while on the lower dose, **and**
- Not being used in combination with an opiate.

Coverage Duration: thru benefit

Effective: 2/06/2019

Posted: 2/15/2019